Results 231 to 240 of about 59,572 (271)
Some of the next articles are maybe not open access.
Treatment-Resistant Schizophrenia
Psychiatric Clinics of North America, 2016Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. In terms of the underlying mechanisms of the development of TRS, progress has been made for the elucidation of the neurochemical ...
Helio, Elkis, Peter F, Buckley
openaire +2 more sources
Management of treatment resistance in schizophrenia
Biological Psychiatry, 2001A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of the second-generation antipsychotics. The need for accurate evaluation will increase further as other new antipsychotic medications are developed. Patients with schizophrenia may manifest poor
R R, Conley, D L, Kelly
openaire +2 more sources
Treatment-Resistant Schizophrenia
The Primary Care Companion For CNS DisordersThe Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who ...
Carol S, Lim +5 more
+5 more sources
Treatment-Resistant Schizophrenia
Psychiatric Clinics of North America, 2007This article opens with a brief history of pharmacologic treatment of schizophrenia. It then discusses the definition and treatment of treatment-resistant schizophrenia, with particular attention to clinical, biological and neuroimaging correlates, as well as the best treatment options, including the use of clozapine in patients who meet the definition
openaire +2 more sources
Treatment-Resistant Schizophrenia
The Journal of Clinical Psychiatry, 2021Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of sufficient dose, duration, and adherence. Several demographic, clinical, and neurologic predictors are associated with TRS.
Correll, Christoph U., Howes, Oliver D.
openaire +3 more sources
Treatment resistance in schizophrenia
Psychiatry, 2005Abstract In a substantial proportion of people with schizophrenia the illness shows a poor response to antipsychotic medication. Failure to achieve remission even after the first episode is limited to relatively few cases, and more commonly patients become progressively unresponsive to medication.
Thomas R.E. Barnes, Serdar Dursun
openaire +1 more source
Treatment-Resistant Schizophrenia
The Journal of Clinical Psychiatry, 2019A significant minority of patients (about one quarter to one third) will have a poor response to first-line antipsychotics and be considered treatment-resistant. In this chapter, I outline a sequential approach to treatment-resistant schizophrenia.
openaire +3 more sources
An approach to treatment resistance in schizophrenia
British Journal of Psychiatry, 1999Currently, patients with schizophrenia are usually considered refractory to treatment if they continue to be floridly symptomatic despite receiving treatment with conventional antipsychotic agents. Attempts to improve their response by increasing the dosage, adding supplementary drugs, or switching to agents of another class have not been very ...
openaire +2 more sources
Managing patients with “treatment‐resistant” schizophrenia
Medical Journal of Australia, 2003Patients who fail to respond adequately to pharmacological treatment present an ongoing therapeutic challenge. The term "incomplete recovery" (IR) is preferred to the current term "treatment resistance" to describe these patients. IR should be considered from a multidimensional perspective that includes a broad range of symptoms and functional ...
Christos, Pantelis, Timothy J R, Lambert
openaire +2 more sources
Cannabidiol monotherapy for treatment-resistant schizophrenia
Journal of Psychopharmacology, 2006Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients ...
Antonio Waldo, Zuardi +6 more
openaire +2 more sources